Assessment of Cardiac Myosin-binding Protein C Levels in Coronavirus Disease 2019

Abstract

Objective: This study aimed to evaluate cardiac myosin-binding protein C (cMyBP-C) levels in patients with COVID-19. Materials and Methods: Overall, 187 patients were enrolled in the study. Patients with mild–moderate and severe–critical illness constituted groups 0 and 1, respectively. Results: Admission to the intensive care unit and hospitalization period were significantly higher in group 1. Hemoglobin levels, lymphocyte count, and albumin levels were significantly lower, and lactate dehydrogenase, C-reactive protein (CRP), D-dimer, cardiac troponin I (cTnI), and procalcitonin levels, prothrombin time (PT), and CRP/lymphocyte ratio were higher in group 1 patients compared to group 0 patients. cTnI and CRP/lymphocyte ratio were higher, and ferritin/procalcitonin and albumin/CRP ratios were lower in deceased patients than in surviving patients, while MyBP-C levels were similar in the two groups. Multivariate regression analysis revealed that lymphocyte count and urea levels were independent predictors of mortality. Receiver Operating Characteristic (ROC) curve analysis showed that cTnI level and ferritin/procalcitonin, CRP/lymphocyte, and albumin/CRP ratios were valuable biochemical parameters for predicting mortality in patients with COVID-19. Conclusion: cMyBP-C level may not be a valuable tool for predicting the severity or prognosis of COVID-19.

Keywords

• Cardiac myosin-binding protein C
• Coronavirus disease 2019
• infection

References

1. 1. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Bitter PT, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med 2021; 9(3): 251-9. google scholar
2. 2. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front. Immunol 2020; 11: 1949. google scholar 3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-80. google scholar
3. 4. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020; 8: 420-2. google scholar
4. 5. Cappannoli L, Scacciavillani R, Iannaccone G, Anastasia G, Di Giusto F, Loria V, et al. 2019 novel-coronavirus: cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications. Chronic Dis Transl Med 2020; 6(4): 246-50. google scholar
5. 6. Wei JF, Huang FY, Xiong TY, Liu Q, Chen H, Wang H. Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis. Heart 2020; 106(15): 1154-9. google scholar 7. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-5. google scholar
6. 8. Tajbakhsh A, Hayat SMG, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther 2021; 19(3): 345-7. google scholar
7. 9. Previs MJ, Beck Previs S, Gulick J, Robbins J, Warshaw DM. Molecular mechanics of cardiac myosin-binding protein C in native thick filaments. Science 2012; 337(6099): 1215-8. google scholar
8. 10. Bhuiyan MS, Gulick J, Osinska H, Gupta M, Robbins J. Determination of the critical residues responsible for cardiac myosin binding protein C’s interactions. J Mol Cell Cardiol 2012; 53(6): 838-47. google scholar

9. 11. El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, et al. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol 2007; 43(2): 223-9. google scholar
10. 12. Decker RS, Nakamura S, Winegrad S. The dynamic role of cardiac myosin binding protein-C during ischemia. J Mol Cell Cardiol 2012; 52: 1145-54. google scholar
11. 13. El-Armouche A, Boknik P, Dobrev D. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation 2006; 114: 670-80. google scholar
12. 14. Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL, et al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol 2012; 52(1): 154-64. google scholar
13. 15. Baker JO, Tyther R, Liebetrau C, Clark J, Howarth R, Patterson T, et al. Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res Cardiol 2015; 110(3): 23. google scholar
14. 16. China’s National Health Commission Guidelines for COVID-19 Treatment (7th edition). Available from: https://www.elotus. org/promo-files/COVID 19_resources/Guidance%20for%20 Corona%20Virus%20Disease%202019%20(English%207th%20 Edition%20Draft).pdf. google scholar
15. 17. Khan IH, Zahra SA, Zaim S, Harky AE. At the heart of COVID-19. J Card Surg 2020; 35(6):1287-94. google scholar
16. 18. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W et al. Suspected myocardial injury in patients with COVID- 19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol 2020; 311: 116-21. google scholar
17. 19. Katus HA, Remppis A, Scheffold T, Diederich KW. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991; 67: 1360-7. google scholar
18. 20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497-506. google scholar
19. 21. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama 2020; 323(11): 1061-9. google scholar
20. 22. Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci 2020: 253; 117723. google scholar
21. 23. Januzzi JL. Troponin and BNP use in COVID-19. American College of Cardiology. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19. Accessed 21 Oct 2020. google scholar
22. 24. Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD, et al. The impact of 2019 novel coronavirus on heart injury: a systematic review and meta-analysis. Prog Cardiovasc Dis 2020; 63(4):5 18-24. google scholar
23. 25. Parohan M, Yaghoubi S, Seraji A. Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Eur Heart J Acute Cardiovasc Care 2020; 9(6): 665-77. google scholar
24. 26. Chapman AR, Bularga A, Mills NL. High-sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation 2020; 141(22): 1733-5. google scholar
25. 27. Li L, Zhou Q, Xu J. changes of laboratory cardiac markers and mechanisms of cardiac injury in coronavirus disease 2019. Biomed Res Int 2020; 2020: 7413673. google scholar
26. 28. Kaier TE, Stengaard C, Marjot J, Serensen JT, Alaour B, Stavropoulou-Tatla S, et al. Cardiac myosin-binding protein C to diagnose acute myocardial infarction in the pre-hospital setting. J Am Heart Assoc 2019; 8(15): e013152. google scholar
27. 29. Kuster DWD, Cardenas-Ospina A, Miller L, Liebetrau C, Troidl C, Nef HM, et al. Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. Am J Physiol Heart Circ Physiol 2014; 306: 547-56. google scholar
28. 30. Govindan S, Kuster DWD, Lin B, Kahn DJ, Jeske WP, Walenga JM, et al. Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. Am J Cardiovasc Dis 2013; 3(2): 60-70. google scholar
29. 31. Biebrer S, Kraechan A, Hellmuth JC, Muenchhoff M, Scherer C, Schroeder I, et al. Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury. Infection 2021; 49(3): 491-500. google scholar
30. 32. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation 2020; 142: 342-53. google scholar
31. 33. D’alto M, Marra AM, Severino S, Salzano A, Romeo E, De Rosa R, et al. Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS. Crit Care 2020; 24(1): 670. google scholar
32. 34. Moody WE, Mahmoud-Elsayed HM, Senior J, Gul U, Khan-Kheil AM, Horne Si, et al. Impact of right ventricular dysfunction on mortality in patients hospitalized with COVID-19, according to race . CJC Open 2021; 3(1): 91-100. google scholar
33. 35. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents 2020; 56(2): 106051. google scholar
34. 36. Wang L. C-reactive protein levels in the early stage of COVID-19 Med Mal Infect 2020; 50(4): 332-4. google scholar
35. 37. Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect 2020; 81(3): 452-82. google scholar
36. 38. Erdal GS, Polat O, Erdem GU, Korkusuz R, Hindilerden F, Yilmaz M, et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol 2021; 24: 1-9. google scholar